All business news articles
-
NewsSandoz partners with Samsung Bioepis to accelerate biosimilar pipeline
New licensing, development and commercialisation agreement could expand Sandoz’s pipeline by to up to 32 assets.
-
NewsNeuro-specialist Lundbeck hires new AI lead
New recruit brings over 15 years of leadership experience to the brain health-focused biopharmaceutical company.
-
NewsChiesi and Bespak further collaboration to advance UK production of low carbon inhalers
Partnership increases industrial scale of low carbon pressurised metered dose inhalers (pMDIs), accelerating pharma’s transition to a more sustainable option.
-
NewsGSK grants rare disease firm Alfasigma rights to linerixibat for $690m
Licence agreement with the Italy-based pharma company to advance GSK’s ambitions in rare disease.
-
NewsFDA revises PK study approach in new biosimilar draft guidance
Sandoz is also adjusting its global strategy by recruiting Armin Metzger as President of Biosimilar Development, Manufacturing & Supply.
-
NewsCSL breaks ground on $1.5bn Illinois plasma therapy facility expansion
US manufacturing investment forms part of the firm’s efforts to increase its domestic presence and support its supply network.
-
NewsSanofi gains access to first-in-class JAK inhibitor through $1.5bn licensing deal
Oral small molecule therapy rovadicitnib from Sino Biopharmaceutical offers potential to advance the pharma company’s haematology portfolio.
-
NewsUCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene
License agreement involves development of ATG-201, a B cell-depleting bispecific T-cell engager, supporting the biopharma company’s immunology pipeline.
-
NewsFirst mRNA COVID-19/flu combination vaccine set for European approval
CHMP backs Moderna’s mCombriax vaccine for adults aged 50 and over.
-
NewsNovo Nordisk expands oral GLP-1 manufacturing capacity in Ireland
Near €500 million investment will increase the firm’s capacity to produce tablet versions of its obesity and diabetes medicines.
-
NewsCharles River Laboratories parts ways with its CDMO business
Aims to further strengthen and broaden its portfolio in order to drive long-term growth, greater efficiency and operational excellence.
-
NewsNovartis to site fifth radioligand therapy manufacturing facility in Texas
Investment to support production of radiopharmaceutical cancer therapies and forms part of Novartis’ planned $23 billion investment in its US capabilities.
-
NewsNovo Nordisk strikes $2.1bn oral obesity biologic deal with Vivtex
Drug delivery partnership to advance next-generation oral therapies and help Novo Nordisk expand its obesity and diabetes portfolio.
-
NewsGSK acquires TGF-beta protein firm 35Pharma for nearly $1bn
Acquisition will help GSK scale its pipeline for respiratory, immunology and inflammatory diseases.
-
NewsFDA drafts new ultra-rare disease therapy guidance
Agency’s planned framework is the first to support the approval process for new ultra-rare disease treatments.
-
NewsLilly's Omvoh demonstrates long-term potential in Crohn’s
New late-stage data shows the drug enabled the majority of IBD patients to stay steroid free over three years of Omvoh treatment.
-
NewsDaiichi Sankyo picks Dr John Tsai to head up R&D
The ex-Novartis drug development head will lead the pharmaceutical company’s global R&D operations.
-
NewsJohnson & Johnson invests $1bn in US cell therapy manufacturing
New Pennsylvania plant forms part of the pharma company’s $55 billion commitment to expand its US manufacturing footprint before the end of the decade.
-
NewsGSK wins dual EU approval for its ultra-long-acting biologic Exdensur
The European Commission’s decision covers the treatment’s use in severe asthma and chronic rhinosinusitis.
-
NewsNovartis bolsters the case for Vanrafia’s full approvals in IgA nephropathy
Phase III results will support the firm’s planned filings for traditional approvals later in 2026, following last year’s US and China accelerated approvals.